Analysts forecast that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will announce earnings per share of ($1.08) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Alder Biopharmaceuticals’ earnings. The highest EPS estimate is ($0.87) and the lowest is ($1.54). Alder Biopharmaceuticals posted earnings of ($0.97) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 11.3%. The firm is expected to report its next quarterly earnings report on Thursday, February 22nd.
On average, analysts expect that Alder Biopharmaceuticals will report full year earnings of ($5.14) per share for the current fiscal year, with EPS estimates ranging from ($5.94) to ($4.50). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.90) per share, with EPS estimates ranging from ($5.42) to ($2.84). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Alder Biopharmaceuticals.
Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.29. During the same quarter in the prior year, the business earned ($0.70) EPS.
Shares of Alder Biopharmaceuticals (NASDAQ:ALDR) opened at $13.80 on Wednesday. The firm has a market cap of $934.45, a PE ratio of -2.57 and a beta of 2.60. Alder Biopharmaceuticals has a 12 month low of $8.60 and a 12 month high of $25.45.
In related news, insider Mark James Litton sold 16,519 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $10.80, for a total transaction of $178,405.20. Following the completion of the sale, the insider now directly owns 116,451 shares in the company, valued at $1,257,670.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Alder Biopharmaceuticals by 5.5% during the second quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after buying an additional 187,871 shares during the period. Janus Henderson Group PLC bought a new stake in Alder Biopharmaceuticals during the second quarter valued at approximately $36,956,000. State Street Corp grew its position in Alder Biopharmaceuticals by 9.4% during the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after buying an additional 167,642 shares during the period. Emerald Advisers Inc. PA grew its position in Alder Biopharmaceuticals by 9.6% during the fourth quarter. Emerald Advisers Inc. PA now owns 1,730,028 shares of the biopharmaceutical company’s stock valued at $19,809,000 after buying an additional 151,551 shares during the period. Finally, Pictet Asset Management Ltd. grew its position in Alder Biopharmaceuticals by 159.4% during the third quarter. Pictet Asset Management Ltd. now owns 1,650,540 shares of the biopharmaceutical company’s stock valued at $20,219,000 after buying an additional 1,014,290 shares during the period. Institutional investors own 96.78% of the company’s stock.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.